The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer (Q27651832)
scientific article
Language:
(P31) (Q13442814)
(P50) (Q7154482)
(Q55207450)
(Q38546651)
(Q56250407)
(Q109806779)
(P304) 5522-32
(P407) (Q1860)
(P433) 18
(P478) 51
(P577) Thursday, September 25, 2008
(P1433) (Q900316)
(P1476) "The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer" (language: en)
(P2093) Adrian J Folkes
Khatereh Ahmadi
Sonia Alix
Stewart J Baker
Gary Box
Irina S Chuckowree
Paul Depledge
Suzanne A Eccles
Lori S Friedman
Angela Hayes
Timothy C Hancox
Arumugam Kugendradas
Letitia Lensun
Pauline Moore
Alan G Olivero
Jodie Pang
Sonal Patel
Giles H Pergl-Wilson
Florence I Raynaud
Anthony Robson
Nahid Saghir
Sukhjit Sohal
Mark H Ultsch
Melanie Valenti
Heidi J A Wallweber
Nan Chi Wan
Christian Wiesmann
Alexander Zhyvoloup
Stephen J Shuttleworth
(P2860) (Q40410776)
other details
description scientific article

External Links